KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Intangibles: 2021-2025

Historic Intangibles for Regeneron Pharmaceuticals (REGN) over the last 3 years, with Sep 2025 value amounting to $1.4 billion.

  • Regeneron Pharmaceuticals' Intangibles rose 23.28% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 23.28%. This contributed to the annual value of $1.1 billion for FY2024, which is 10.59% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Intangibles of $1.4 billion as of Q3 2025, which was up 2.16% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Intangibles peaked at $1.4 billion during Q3 2025, and registered a low of $6.7 million during Q4 2021.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Intangibles value was $1.1 billion (recorded in 2024), while the average stood at $1.1 billion.
  • Data for Regeneron Pharmaceuticals' Intangibles shows a peak YoY surged of 13,564.18% (in 2022) over the last 5 years.
  • Regeneron Pharmaceuticals' Intangibles (Quarterly) stood at $6.7 million in 2021, then spiked by 13,564.18% to $915.5 million in 2022, then increased by 13.45% to $1.0 billion in 2023, then grew by 10.59% to $1.1 billion in 2024, then increased by 23.28% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.2 billion during Q1 2025.